Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy
Authors:
Open Access
- 28 July 2021
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 19 (1) , 1-12
Abstract
Background: 211At is a high-energy α-ray emitter with a relatively short half-life and a high cytotoxicity for cancer cells. Its dispersion can be imaged using clinical scanners, and it can be produced in cyclotrons without the use of nuclear fuel material. This study investigated the biodistribution and the antitumor effect of 211At-labeled gold nanoparticles (211At-AuNP) administered intratumorally. Results: AuNP with a diameter of 5, 13, 30, or 120 nm that had been modified with poly (ethylene glycol) methyl ether (mPEG) thiol and labeled with 211At (211At-AuNP-S-mPEG) were incubated with tumor cells, or intratumorally administered to C6 glioma or PANC-1 pancreatic cancers subcutaneously transplanted into rodent models. Systemic and intratumoral distributions of the particles in the rodents were then evaluated using scintigraphy and autoradiography, and the changes in tumor volumes were followed for about 40 days. 211At-AuNP-S-mPEG was cytotoxic when it was internalized by the tumor cells. After intratumoral administration, 211At-AuNP-S-mPEG became localized in the tumor and did not spread to systemic organs during a time period equivalent to 6 half-lives of 211At. Tumor growth was strongly suppressed for both C6 and PANC-1 by 211At-AuNP-S-mPEG. In the C6 glioma model, the strongest antitumor effect was observed in the group treated with 211At-AuNP-S-mPEG with a diameter of 5 nm. Conclusions: The intratumoral single administration of a simple nanoparticle, 211At-AuNP-S-mPEG, was shown to suppress the growth of tumor tissue strongly in a particle size-dependent manner without radiation exposure to other organs caused by systemic spread of the radionuclide. GraphicKeywords
All Related Versions
Funding Information
- Japan Society for the Promotion of Science (JP18K07674, JP20H05675, JP20H00404)
- Program on Open Innovation Platform with Enterprises, Research Institute and Academia (JPMJOP1721)
This publication has 31 references indexed in Scilit:
- Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastomaJournal of Neuro-Oncology, 2013
- Association Between Treatment With Brachytherapy vs Whole-Breast Irradiation and Subsequent Mastectomy, Complications, and Survival Among Older Women With Invasive Breast CancerJAMA, 2012
- Seeded Growth Synthesis of Uniform Gold Nanoparticles with Diameters of 15−300 nmThe Journal of Physical Chemistry C, 2011
- Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicityChemical Society Reviews, 2009
- Biodistribution of colloidal gold nanoparticles after intravenous administration: Effect of particle sizeColloids and Surfaces B: Biointerfaces, 2008
- Particle size-dependent organ distribution of gold nanoparticles after intravenous administrationBiomaterials, 2008
- PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism StudiesDrug Metabolism and Disposition, 2007
- Neoadjuvante interstitielle HDR-Brachytherapie in Kombination mit Chemotherapie bei Patientinnen mit MammakarzinomStrahlentherapie und Onkologie, 2006
- Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticlesJournal of Pharmaceutical Sciences, 2001
- Phase III trial of high- vs. low-dose-rate interstitial radiotherapy for early mobile tongue cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2001